Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Gastric Adenocarcinoma
Clinical trial register · United States · industry-sponsored

Gastric Adenocarcinoma Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 10 Arizona 6 Texas 6 Florida 5 Missouri 4
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Gastric Adenocarcinoma trials in the USA

15 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Gilead Sciences
Phase 2
120
Massachusetts, New York
2026-08-07
Recruiting
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
NCT07529808Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma
BigHat Biosciences, Inc.
Phase 1/2
164
California, Virginia
2026-07-16
Recruiting
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
570
Minnesota
2026-06-30
Recruiting
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
NCT07544589Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
Dispatch Biotherapeutics
Phase 1
66
California, Florida, Massachusetts, Ohio, Tennessee, Utah
2026-04-13
Recruiting
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
NCT07454642Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
Avacta Life Sciences Ltd
Phase 1
174
Arizona, Florida, Illinois, Michigan, New York, Texas, Virginia
2026-03-31
Recruiting
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT07277413NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
DrugIDE397
IDEAYA Biosciences
Phase 1
260
Arizona, California, District of Columbia, Florida, Illinois, Minnesota, Nebraska, New Jersey
2026-03-04
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
NCT07284186Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Plexium, Inc.
Phase 1
155
Arizona, California, Massachusetts, Missouri, New York, North Carolina, Ohio, Texas
2025-12-01
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Normunity AccelCo, Inc.
Phase 1
150
Colorado, Connecticut, District of Columbia, Massachusetts, Minnesota, Missouri, New Jersey, Ohio
2025-10-30
Active, closed
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
SystImmune Inc.
Phase 1
160
Arizona, California, Colorado, Connecticut, Louisiana, Michigan, New Jersey, Tennessee
2025-07-30
Recruiting
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Kyowa Kirin Co., Ltd.
Phase 1
101
Arizona, California, Florida, Missouri, Texas, Washington
2024-01-18
Recruiting
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
NCT06038578Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Toray Industries, Inc
Phase 2
146
California, Texas
2023-10-04
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
398
California, Illinois, Kansas, New Jersey, New York, North Carolina, Texas, Washington
2022-06-07
Active, closed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
ALX Oncology Inc.
Phase 2/3
127
California, Tennessee, Virginia, Washington
2022-01-15
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
40
Arizona, Colorado, District of Columbia, Missouri, New Mexico, North Carolina, Ohio, Washington
2020-09-15
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
Klus Pharma Inc.
Phase 1/2
1,410
California, Florida, Michigan, Oklahoma, Oregon, Texas, Virginia
2020-02-28
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/gastric-adenocarcinoma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies listing the condition Gastric Adenocarcinoma.

How many Gastric Adenocarcinoma trials are recruiting in the US?

11 of the 15 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gastric Adenocarcinoma), 15 studies
PhaseStudiesRecruitingShare
Phase 18753.3%
Phase 23220%
Phase 1/22113.3%
Phase 2/3106.7%
Phase 3116.7%

Most active sponsors

Lead sponsors with the most studies (Gastric Adenocarcinoma)
Lead sponsorStudiesRecruiting
Astellas Pharma Global Development, Inc.22
ALX Oncology Inc.10
Avacta Life Sciences Ltd11
BigHat Biosciences, Inc.11
Dispatch Biotherapeutics11
Gilead Sciences11
IDEAYA Biosciences11
Klus Pharma Inc.10
Kyowa Kirin Co., Ltd.11
Normunity AccelCo, Inc.11

Top states

Top states (Gastric Adenocarcinoma), by number of studies with a site there
StateStudies
California10
Arizona6
Texas6
Florida5
Massachusetts4
Missouri4
New Jersey4
New York4
Ohio4
Virginia4
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.